Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.59 |
| ▸ | KMO | O15229 | 3/20 | 0.57 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | USP5 | P45974 | 1/20 | 0.53 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.53 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.52 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5848843 | 0.89 | TSHR (0.55) | TSHRKMOHSD11B1SRD5A2 | |
| SCHEMBL6360749 | 0.89 | TSHR (0.55) | TSHRKMOHSD11B1SRD5A2 | |
| SCHEMBL5849219 | 0.87 | HDAC3 (0.58) | TSHRKMOHSD11B1LMNASRD5A2 | |
| SCHEMBL7862868 | 0.86 | SMN1; SMN2 (0.64) | TSHRKMONR4A2KMT2AUSP5 | |
| SCHEMBL11637468 | 0.85 | USP5 (0.50) | TSHRNR4A2KMT2AUSP5FFAR1 | |
| SCHEMBL11706074 | 0.85 | CA2 (0.51) | TSHRNR4A2KMT2AUSP5FFAR1 | |
| SCHEMBL2875993 | 0.84 | USP5 (0.49) | TSHRKMONR4A2KMT2AUSP5 | |
| SCHEMBL11089924 | 0.84 | USP5 (0.49) | TSHRNR4A2KMT2AUSP5FFAR1 | |
| SCHEMBL10598079 | 0.84 | KMT2A (0.58) | TSHRNR4A2KMT2AUSP5FFAR1 | |
| SCHEMBL11743831 | 0.84 | USP5 (0.49) | TSHRNR4A2KMT2AUSP5FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 115 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4813800-B2 | — | — | 2011-11-09 | — | — | JP | claimed |
| US-20060142358-A1 | Kynurenine 3-hydroxylase inhibitors for the treatment of diabetes | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2006-06-29 | — | — | US | claimed |
| EP-1581215-A1 | KYNURENINE 3-HYDROXYLASE INHIBITORS FOR THE TREATMENT OF DIABETES | MERCK PATENT GmbH (DE) | 2005-10-05 | — | — | EP | claimed |
| EP-1581216-A1 | KYNURENINE 3-HYDROXYLASE INHIBITORS FOR THE TREATMENT OF DIABETES BY INCREASING THE NUMBER OF ISLETS OF LANGERHANS CELLS | MERCK PATENT GmbH (DE) | 2005-10-05 | — | — | EP | claimed |
| WO-2004060368-A1 | KYNURENINE 3-HYDROXYLASE INHIBITORS FOR THE TREATMENT OF DIABETES BY INCREASING THE NUMBER OF ISLETS OF LANGERHANS CELLS | MERCK PATENT GMBH (DE) | 2004-07-22 | — | — | WO | claimed |
| WO-2004060369-A1 | KYNURENINE 3-HYDROXYLASE INHIBITORS FOR THE TREATMENT OF DIABETES | MERCK PATENT GMBH (DE) | 2004-07-22 | — | — | WO | claimed |
| EP-0624152-B1 | PROCESS FOR PREPARING KETONE ENANTIOMER | PFIZER (US) | 1996-11-13 | — | — | EP | claimed |
| US-5466880-A | Process for preparing ketone enantiomer | PFIZER INC. (US) | 1995-11-14 | — | — | US | claimed |
| EP-0624152-A1 | PROCESS FOR PREPARING KETONE ENANTIOMER. | PFIZER (US) | 1994-11-17 | — | — | EP | claimed |
| WO-1993012062-A1 | PROCESS FOR PREPARING KETONE ENANTIOMER | PFIZER INC. (US) | 1993-06-24 | — | — | WO | claimed |
| EP-0295050-B1 | PROCESS FOR PREPARING A 4,4-DIPHENYLBUTANOIC ACID DERIVATIVE | PFIZER INC. (US) | 1991-04-17 | — | — | EP | claimed |
| EP-0295050-A1 | Process for preparing a 4,4-diphenylbutanoic acid derivative | PFIZER INC. (US) | 1988-12-14 | — | — | EP | claimed |
| US-4777288-A | Process for preparing a 4,4-diphenylbutanoic acid derivative | PFIZER INC. (US) | 1988-10-11 | — | — | US | claimed |
| JP-1009953-A | — | — | None | — | — | JP | disclosed |
| US-10829427-B2 | Naphthoquinones, pro-drugs, and methods of use thereof | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2020-11-10 | — | — | US | disclosed |
| US-10829427-B2 | Naphthoquinones, pro-drugs, and methods of use thereof | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2020-11-10 | — | — | US | disclosed |
| US-4136184-A | TRANQUILIZERS, ANTICONVULSANTS, MUSCLE RELAXANTS | SANDOZ, INC. (US) | 1979-01-23 | — | — | US | disclosed |
| US-4055644-A | CNS DEPRESSANTS | SANDOZ, INC. (US) | 1977-10-25 | — | — | US | disclosed |
| US-4052395-A | AGRICULTURAL FUNGICIDAL COMPOSITIONS CONTAINING 6-(SUBSTITUTED PHENYL)-PYRIDAZINONES AND SAID PYRIDAZINONES | SANKYO COMPANY LIMITED (JA) | 1977-10-04 | — | — | US | disclosed |
| US-3931176-A | CNS DEPRESSANT | SANDOZ INC. (US) | 1976-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10829427-B2 | Naphthoquinones, pro-drugs, and methods of use thereof | NQO1, RECQL, ABCB1 | TSHR 3159/4885KMO 2036/4885NR4A2 469/4885 |
| US-20060142358-A1 | Kynurenine 3-hydroxylase inhibitors for the treatment of diabetes | KYNU, KMO, AADAT | TSHR 2294/4885KMO 2/4885NR4A2 2009/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.